{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:05:47Z","timestamp":1763017547669},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,7,6]],"date-time":"2015-07-06T00:00:00Z","timestamp":1436140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,7,6]],"date-time":"2015-07-06T00:00:00Z","timestamp":1436140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1038\/bmt.2015.149","type":"journal-article","created":{"date-parts":[[2015,7,6]],"date-time":"2015-07-06T15:27:39Z","timestamp":1436196459000},"page":"1286-1292","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning"],"prefix":"10.1038","volume":"50","author":[{"given":"A R","family":"Rezvani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A S","family":"Kanate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Efron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H E","family":"Kohrt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"Shizuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G G","family":"Laport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D B","family":"Miklos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J E","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L J","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W-K","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R S","family":"Negrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Strober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Lowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,6]]},"reference":[{"key":"BFbmt2015149_CR1","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918\u20133927.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015149_CR2","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051\u20131054.","journal-title":"Lancet"},{"key":"BFbmt2015149_CR3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540\u20131545.","journal-title":"N Engl J Med"},{"key":"BFbmt2015149_CR4","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1093\/annonc\/mdq035","volume":"21","author":"JM Calvo-Villas","year":"2010","unstructured":"Calvo-Villas JM, Martin A, Conde E, Pascual A, Heras I, Varela R et al. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. Ann Oncol 2010; 21: 1891\u20131897.","journal-title":"Ann Oncol"},{"key":"BFbmt2015149_CR5","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/annonc\/mdn404","volume":"19","author":"MR Bishop","year":"2008","unstructured":"Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 2008; 19: 1935\u20131940.","journal-title":"Ann Oncol"},{"key":"BFbmt2015149_CR6","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1182\/blood-2012-03-417808","volume":"119","author":"IF Khouri","year":"2012","unstructured":"Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 2012; 119: 6373\u20136378.","journal-title":"Blood"},{"key":"BFbmt2015149_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","volume":"26","author":"AR Rezvani","year":"2008","unstructured":"Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 211\u2013217.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015149_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2141.2008.07365.x","volume":"143","author":"AR Rezvani","year":"2008","unstructured":"Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143: 395\u2013403.","journal-title":"Br J Haematol"},{"key":"BFbmt2015149_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","volume":"27","author":"KJ Thomson","year":"2009","unstructured":"Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 426\u2013432.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015149_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","volume":"31","author":"AJ Peniket","year":"2003","unstructured":"Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667\u2013678.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015149_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bbmt.2009.08.011","volume":"16","author":"HM Lazarus","year":"2010","unstructured":"Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2010; 16: 35\u201345.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015149_CR12","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","volume":"120","author":"U Bacher","year":"2012","unstructured":"Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 2012; 120: 4256\u20134262.","journal-title":"Blood"},{"key":"BFbmt2015149_CR13","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","volume":"29","author":"RJ van Kampen","year":"2011","unstructured":"van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342\u20131348.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015149_CR14","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","volume":"102","author":"K van Besien","year":"2003","unstructured":"van Besien K, Loberiza FR Jr., Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521\u20133529.","journal-title":"Blood"},{"key":"BFbmt2015149_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/JCO.1996.14.2.572","volume":"14","author":"JL Gajewski","year":"1996","unstructured":"Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572\u2013578.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015149_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S1083-8791(00)70009-7","volume":"6","author":"JP Radich","year":"2000","unstructured":"Radich JP, Gooley T, Sanders JE, Anasetti C, Chauncey T, Appelbaum FR . Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000; 6: 272\u2013279.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015149_CR17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/sj.bmt.1700989","volume":"20","author":"T Tsai","year":"1997","unstructured":"Tsai T, Goodman S, Saez R, Schiller G, Adkins D, Callander N et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 1997; 20: 859\u2013863.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015149_CR18","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","volume":"97","author":"PA McSweeney","year":"2001","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390\u20133400.","journal-title":"Blood"},{"key":"BFbmt2015149_CR19","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/sj.bmt.1702392","volume":"25","author":"A Nagler","year":"2000","unstructured":"Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R . Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021\u20131028.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015149_CR20","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","volume":"104","author":"E Morris","year":"2004","unstructured":"Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865\u20133871.","journal-title":"Blood"},{"key":"BFbmt2015149_CR21","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","volume":"98","author":"IF Khouri","year":"2001","unstructured":"Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595\u20133599.","journal-title":"Blood"},{"key":"BFbmt2015149_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1182\/blood.V99.1.75","volume":"99","author":"P Corradini","year":"2002","unstructured":"Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 75\u201382.","journal-title":"Blood"},{"key":"BFbmt2015149_CR23","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","volume":"111","author":"ML Sorror","year":"2008","unstructured":"Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R . Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111: 446\u2013452.","journal-title":"Blood"},{"key":"BFbmt2015149_CR24","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa050642","volume":"353","author":"R Lowsky","year":"2005","unstructured":"Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353: 1321\u20131331.","journal-title":"N Engl J Med"},{"key":"BFbmt2015149_CR25","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood-2009-03-211441","volume":"114","author":"HE Kohrt","year":"2009","unstructured":"Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009; 114: 1099\u20131109.","journal-title":"Blood"},{"key":"BFbmt2015149_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579\u2013586.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015149_CR27","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0360-3016(97)00504-X","volume":"39","author":"SL Wolden","year":"1997","unstructured":"Wolden SL, Tate DJ, Hunt SA, Strober S, Hoppe RT . Long-term results of total lymphoid irradiation in the treatment of cardiac allograft rejection. Int J Radiat Oncol Biol Phys 1997; 39: 953\u2013960.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFbmt2015149_CR28","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1097\/00007890-200205150-00005","volume":"73","author":"MT Millan","year":"2002","unstructured":"Millan MT, Shizuru JA, Hoffmann P, Dejbakhsh-Jones S, Scandling JD, Grumet FC et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73: 1386\u20131391.","journal-title":"Transplantation"},{"key":"BFbmt2015149_CR29","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1038\/sj.leu.2404335","volume":"20","author":"F Baron","year":"2006","unstructured":"Baron F, Sandmaier BM . Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 2006; 20: 1690\u20131700.","journal-title":"Leukemia"},{"key":"BFbmt2015149_CR30","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015149_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bbmt.2005.10.023","volume":"12","author":"HM Shulman","year":"2006","unstructured":"Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006; 12: 31\u201347.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015149_CR32","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","volume":"12","author":"R Rodriguez","year":"2006","unstructured":"Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 1326\u20131334.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015149_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","volume":"26","author":"A Sureda","year":"2008","unstructured":"Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455\u2013462.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015149_CR34","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.bmt.1704942","volume":"35","author":"P Anderlini","year":"2005","unstructured":"Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005; 35: 943\u2013951.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015149_CR35","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","volume":"111","author":"IF Khouri","year":"2008","unstructured":"Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530\u20135536.","journal-title":"Blood"},{"key":"BFbmt2015149_CR36","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1200\/JCO.2004.09.092","volume":"22","author":"MP Escalon","year":"2004","unstructured":"Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22: 2419\u20132423.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015149_CR37","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","volume":"14","author":"LM Burroughs","year":"2008","unstructured":"Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1279\u20131287.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015149_CR38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","volume":"14","author":"P Hari","year":"2008","unstructured":"Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236\u2013245.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015149_CR39","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.bbmt.2012.03.012","volume":"18","author":"G Messina","year":"2012","unstructured":"Messina G, Giaccone L, Festuccia M, Irrera G, Scortechini I, Sorasio R et al. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. Biol Blood Marrow Transplant 2012; 18: 1600\u20131607.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015149_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-014-0098-9","volume":"8","author":"F Baron","year":"2015","unstructured":"Baron F, Zachee P, Maertens J, Kerre T, Ory A, Seidel L et al. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2\u2009Gy TBI or ATG plus 8\u2009Gy TLI: a phase II randomized study from the Belgian Hematological Society. J Hematol Oncol 2015; 8: 4.","journal-title":"J Hematol Oncol"},{"key":"BFbmt2015149_CR41","doi-asserted-by":"crossref","unstructured":"Benjamin J, Laport GG, Tate K, Galvez L, Armstrong R, Sheehan K et al. Early Infusion Of Donor-Derived CIK Cells As Consolidative Immunotherapy Following Non-Myeloablative Allogeneic Transplantation: Safety and Feasibility (Abstract #899). American Society of Hematology Annual Meeting. New Orleans, LA, 2013.","DOI":"10.1182\/blood.V122.21.899.899"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2015149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015149","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T18:17:17Z","timestamp":1648059437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2015149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,6]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["BFbmt2015149"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.149","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,6]]},"assertion":[{"value":"5 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JEB was a faculty member at Stanford University during the time that this research was conducted, but is now an employee of Amgen. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}